Biography

Amarpreet Sawhney, Ph.D., has served as President, Chief Executive Officer and a member of our Board since co-founding the Company in 2006, and he was elected as Chairman of the Board in June 2014. Dr. Sawhney served as CEO of Augmenix, an affiliate of Ocular Therapeutix, from 2008 until April 2014. In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health in 2014.

Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. He holds M.S. and Ph.D. degrees in Chemical Engineering from the University of Texas at Austin, as well as a B.Tech. in Chemical Engineering from the Indian Institute of Technology, Delhi India.